




**SYFOVRE**<sup>®</sup>  
(pegcetacoplan injection)  
15mg / 0.1mL

EFFECTIVE OCTOBER 1, 2023

Permanent J-code for SYFOVRE: **J2781**

# Billing and Coding Guide

 Phone: 888-APELLIS (888-273-5547) 8 AM-8 PM ET, Monday-Friday

 Portal: [ApellisAssistGA.com](https://ApellisAssistGA.com)

 Website: [SyfovreECP.com](https://SyfovreECP.com)

 Fax: 888-405-6966

**The coding information in this document is provided for informational purposes only, is subject to change, and should not be construed as legal advice.**

This guide is intended to provide general information for submitting claims to payers for reimbursement. In no way should this information be considered a guarantee of coverage or reimbursement for any product or service. Coding and coverage policies change periodically, often without warning. The responsibility to determine coverage and reimbursement parameters and appropriate coding for a particular patient or procedure is always the responsibility of the provider. The codes listed herein may not apply to all patients or to all payers. Providers should exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the services and products furnished to a specific patient. Practices should contact the applicable payer for more information on a payer's coverage, coding, and reimbursement policies.

## INDICATION

SYFOVRE<sup>®</sup> (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

## IMPORTANT SAFETY INFORMATION

### CONTRAINDICATIONS

- SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

Please see additional Important Safety Information throughout and full [Prescribing Information](#).

Apellis

# Coding Information

The following codes may be appropriate when billing for SYFOVRE and its related services.

**Several terms** are used in Geographic Atrophy (GA) to indicate lesion location relative to the fovea

**H35.31X3:**  
WITHOUT SUBFOVEAL INVOLVEMENT

- ⊖ **no** involvement of the fovea
- ⊖ **extra**foveal lesions
- ⊖ **nonsub**foveal lesions
- ⊖ **without** subfoveal lesions

**H35.31X4:**  
WITH SUBFOVEAL INVOLVEMENT

- ⊕ **with** involvement of the fovea
- ⊕ **foveal** lesions
- ⊕ **subfoveal** lesions
- ⊕ **with** subfoveal lesions

The ICD-10-CM codes below are designated for GA<sup>1</sup>

Geographic Atrophy ICD-10-CM Codes <sup>1</sup> Used for diagnosis coding				
Nonexudative age-related macular degeneration (AMD)		Right eye	Left eye	Bilateral
GA	Advanced atrophic <b>without</b> subfoveal involvement	H35.3113	H35.3123	H35.3133
	Advanced atrophic <b>with</b> subfoveal involvement	H35.3114	H35.3124	H35.3134

**Drug Administration CPT Code<sup>2a</sup>**  
Used to report medical procedures and services

CPT code	Description
67028	Intravitreal injection of a pharmacologic agent, separate procedure

This may not be reflective of all CPT codes that may be used for SYFOVRE.

**Modifiers** Used in conjunction with the CPT Code at left to provide further information about the procedure or service

Modifier	Description
-LT	Left eye
-RT	Right eye
-50	Bilateral

This is not an exhaustive list of modifiers, and requirements may vary by payer.

CPT=Current Procedural Terminology; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification.  
<sup>a</sup>CPT codes, descriptions, and material are ©2023 American Medical Association. All rights reserved.

## IMPORTANT SAFETY INFORMATION

### WARNINGS AND PRECAUTIONS

#### • Endophthalmitis and Retinal Detachments

- Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.



Please see additional Important Safety Information throughout and full Prescribing Information.



# Coding Information (cont'd)

The following codes may be appropriate when billing for SYFOVRE and its related services.

HCPCS Code <sup>3</sup> Used for drugs administered by a medical professional		
Permanent J-code	CMS long descriptor <sup>a</sup>	Site of care
<b>J2781</b> effective October 1, 2023	Injection, pegcetacoplan, intravitreal, 1 mg	Physician office and hospital outpatient

J2781 is a permanent, product-specific code assigned by CMS. **Bill 15 units for each SYFOVRE injection.**

<sup>a</sup>Dose descriptor is assigned by CMS; please see full prescribing information for approved dosing.

The JZ modifier is required starting July 1, 2023.<sup>4</sup> Please check with your patient's health plan for specific requirements.

National Drug Code (NDC) <sup>5,6</sup> Used by the FDA as an identifier for drugs	
10-digit NDC for SYFOVRE Many NDCs listed on drug packaging are in a 10-digit format	11-digit NDC for SYFOVRE The 11-digit NDC is derived from the 10-digit code. Many payers require the use of the 11-digit code
73606-020-01	73606-0020-01

Dosage form and strength
Intravitreal injection: 15 mg (0.1 mL of 150 mg/mL solution), clear, colorless to light yellow aqueous solution in a single-dose vial

Revenue Codes <sup>7</sup> For hospital outpatient use only	
Revenue code	Description
0636	Drugs requiring detailed coding
0510	Clinic visit, general

This is not an exhaustive list of revenue codes, and requirements may vary by payer.

CMS=Centers for Medicare and Medicaid Services; HCPCS=Healthcare Common Procedure Coding System.

## IMPORTANT SAFETY INFORMATION

### WARNINGS AND PRECAUTIONS (CONTINUED)

#### • Neovascular AMD

- In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.



Please see additional Important Safety Information throughout and full Prescribing Information.

**SYFOVRE**  
(pegcetacoplan injection)  
15 mg / 0.1 mL

# Sample CMS-1500 Claim Form: Physician Office

Below is a sample CMS-1500 form for SYFOVRE claim submissions.

The sample claim form provided below is for illustrative purposes only. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for the products and services rendered. Providers should contact third-party payers for specific information on their coding, coverage, payment policies, and fee schedules.

**Box 21:**  
Enter the appropriate ICD-10-CM code corresponding to the patient's diagnosis.

**Box 23:**  
If available, report the Prior Authorization number here.

**Shaded area below box 24A:**  
The payer may require the N4 qualifier immediately preceding the 11-digit NDC, the unit of measurement qualifier, and unit quantity.

**Box 24B:**  
Enter the place of service for physician offices.

**Box 24D:**  
Include all appropriate CPT codes, modifiers, and HCPCS codes. The JZ modifier is required starting July 1, 2023.<sup>4</sup>

**Box 24E:**  
Specify the diagnosis letter from Box 21 relating to each CPT/HCPCS code listed in Box 24D.

**Box 24G:**  
Enter the number of units for each CPT/HCPCS code. When using the permanent J-code, bill 15 units for each SYFOVRE injection. Check with each payer for their specific coding requirements.

**NOTE:** Payers may vary in their specific billing and coding requirements. Please check with your patient's health plan to ensure you are providing accurate and complete information.

The JZ modifier is required starting July 1, 2023.<sup>4</sup>

## IMPORTANT SAFETY INFORMATION

### WARNINGS AND PRECAUTIONS (CONTINUED)

#### • Intraocular Inflammation

- In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.

#### • Increased Intraocular Pressure

- Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.



Please see additional Important Safety Information throughout and full Prescribing Information.

# Sample CMS-1450 (UB-04) Claim Form: Hospital Outpatient

Below is a sample CMS-1450 (UB-04) form for SYFOVRE claim submissions.

The sample claim form provided below is for illustrative purposes only. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims for the products and services rendered. Providers should contact third-party payers for specific information on their coding, coverage, payment policies, and fee schedules.

1 Hospital Name		2 Pay-to Name		3a PAT CITY #		4 TYPE OF BILL	
Street Address		Pay-to Address		b MED REG #		5 STATEMENT COVERS PERIOD	
City, State, Zip		Pay-to City, State, Zip		6 FED. TAX NO.		7	
8 PATIENT NAME		9 PATIENT ADDRESS		10		11	
12 PATIENT NAME		13		14		15	
16 BIRTHDATE		17 SEX		18 DATE		19	
20		21		22		23	
24		25		26		27	
28		29		30		31	
32		33		34		35	
36		37		38		39	
40		41		42		43	
44		45		46		47	
48		49		50		51	
52		53		54		55	
56		57		58		59	
60		61		62		63	
64		65		66		67	
68		69		70		71	
72		73		74		75	
76		77		78		79	
80		81		82		83	
84		85		86		87	
88		89		90		91	
92		93		94		95	
96		97		98		99	
100		101		102		103	
104		105		106		107	
108		109		110		111	
112		113		114		115	
116		117		118		119	
120		121		122		123	
124		125		126		127	
128		129		130		131	
132		133		134		135	
136		137		138		139	
140		141		142		143	
144		145		146		147	
148		149		150		151	
152		153		154		155	
156		157		158		159	
160		161		162		163	
164		165		166		167	
168		169		170		171	
172		173		174		175	
176		177		178		179	
180		181		182		183	
184		185		186		187	
188		189		190		191	
192		193		194		195	
196		197		198		199	
200		201		202		203	
204		205		206		207	
208		209		210		211	
212		213		214		215	
216		217		218		219	
220		221		222		223	
224		225		226		227	
228		229		230		231	
232		233		234		235	
236		237		238		239	
240		241		242		243	
244		245		246		247	
248		249		250		251	
252		253		254		255	
256		257		258		259	
260		261		262		263	
264		265		266		267	
268		269		270		271	
272		273		274		275	
276		277		278		279	
280		281		282		283	
284		285		286		287	
288		289		290		291	
292		293		294		295	
296		297		298		299	
300		301		302		303	
304		305		306		307	
308		309		310		311	
312		313		314		315	
316		317		318		319	
320		321		322		323	
324		325		326		327	
328		329		330		331	
332		333		334		335	
336		337		338		339	
340		341		342		343	
344		345		346		347	
348		349		350		351	
352		353		354		355	
356		357		358		359	
360		361		362		363	
364		365		366		367	
368		369		370		371	
372		373		374		375	
376		377		378		379	
380		381		382		383	
384		385		386		387	
388		389		390		391	
392		393		394		395	
396		397		398		399	
400		401		402		403	
404		405		406		407	
408		409		410		411	
412		413		414		415	
416		417		418		419	
420		421		422		423	
424		425		426		427	
428		429		430		431	
432		433		434		435	
436		437		438		439	
440		441		442		443	
444		445		446		447	
448		449		450		451	
452		453		454		455	
456		457		458		459	
460		461		462		463	
464		465		466		467	
468		469		470		471	
472		473		474		475	
476		477		478		479	
480		481		482		483	
484		485		486		487	
488		489		490		491	
492		493		494		495	
496		497		498		499	
500		501		502		503	
504		505		506		507	
508		509		510		511	
512		513		514		515	
516		517		518		519	
520		521		522		523	
524		525		526		527	
528		529		530		531	
532		533		534		535	
536		537		538		539	
540		541		542		543	
544		545		546		547	
548		549		550		551	
552		553		554		555	
556		557		558		559	
560		561		562		563	
564		565		566		567	
568		569		570		571	
572		573		574		575	
576		577		578		579	
580		581		582		583	
584		585		586		587	
588		589		590		591	
592		593		594		595	
596		597		598		599	
600		601		602		603	
604		605		606		607	
608		609		610		611	
612		613		614		615	
616		617		618		619	
620		621		622		623	
624		625		626		627	
628		629		630		631	
632		633		634		635	
636		637		638		639	
640		641		642		643	
644		645		646		647	
648		649		650		651	
652		653		654		655	
656		657		658		659	
660		661		662		663	
664		665		666		667	
668		669		670		671	
672		673		674		675	
676		677		678		679	
680		681		682		683	
684		685		686		687	
688		689		690		691	
692		693		694		695	
696		697		698		699	
700		701		702		703	
704		705		706		707	
708		709		710		711	
712		713		714		715	
716		717		718		719	
720		721		722		723	
724		725		726		727	
728		729		730		731	
732		733		734		735	
736		737		738		739	
740		741		742		743	
744		745		746		747	
748		749		750		751	
752		753		754		755	
756		757		758		759	
760		761		762		763	
764		765		766		767	
768		769		770		771	
772		773		774		775	
776		777		778		779	
780		781		782		783	
784		785		786		787	
788		789		790		791	
792		793		794		795	
796		797		798		799	
800		801		802		803	
804		805		806		807	
808		809		810		811	
812		813		814		815	
816		817		818		819	
820		821		822		823	
824		825		826		827	
828		829		830		831	
832		833		834		835	
836		837		838		839	
840		841		842		843	
844		845		846		847	
848		849		850		851	
852		853		854		855	
856		857		858		859	
860		861		862		863	
864		865		866		867	
868		869		870		871	
872		873		874		875	
876		877		878		879	
880		881		882			

# Tips for completing claim forms:



Use the most appropriate ICD-10-CM and CPT codes associated with each patient's diagnosis and care



When using the permanent J-code J2781, bill 15 units for each SYFOVRE injection



Contact the payer prior to submitting the claim to confirm the payer's method for submission and if supporting documentation is required



Ensure the appropriate documentation that supports the information on the claim form is in the patient's medical record in case the payer requests it



Verify the claim for accuracy and file it as soon as possible, within each payer's filing time limits



Check your contract, or contact provider services at the payer to determine reimbursement

**Questions?** Please reach out to your Apellis Field Reimbursement Manager or the ApellisAssist® program

## ApellisAssist® Here for your patients

The ApellisAssist program can provide assistance on a range of topics, including insurance coverage requirements, claim submission policies and procedures, and billing and coding questions.

### To enroll your patients in ApellisAssist

Register for the portal and submit your request online at [ApellisAssistGA.com](https://ApellisAssistGA.com)



Download the Enrollment Form from [SyfovreECP.com](https://SyfovreECP.com) and fax the completed form to 888-405-6966



Phone: 888-APELLIS (888-273-5547) 8 AM-8 PM ET, Monday-Friday



Website: [SyfovreECP.com](https://SyfovreECP.com)



Portal: [ApellisAssistGA.com](https://ApellisAssistGA.com)



Fax: 888-405-6966



Please see Important Safety Information throughout and full Prescribing Information.

**SYFOVRE**  
(pegcetacoplan injection)  
15 mg / 0.1 mL



# SYFOVRE<sup>®</sup>

(pegcetacoplan injection)  
15 mg / 0.1 mL

## INDICATION

SYFOVRE<sup>®</sup> (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

## IMPORTANT SAFETY INFORMATION

### CONTRAINDICATIONS

- SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with active intraocular inflammation

### WARNINGS AND PRECAUTIONS

#### • Endophthalmitis and Retinal Detachments

- Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

#### • Neovascular AMD

- In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.

#### • Intraocular Inflammation

- In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.

#### • Increased Intraocular Pressure

- Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

### ADVERSE REACTIONS

- Most common adverse reactions (incidence  $\geq 5\%$ ) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

**Please see full Prescribing Information for more information.**

**References:** 1. Lum F, Repka MX, Vicchilli S. How to use the ICD-10 codes for age-related macular degeneration. *EyeNet Magazine*. 2017;9:61–62. 2. Coding for injectable drugs. American Academy of Ophthalmology. Accessed July 18, 2023. <https://www.aao.org/practice-management/coding/injectable-drugs> 3. Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) application summaries and coding recommendations. Centers for Medicare & Medicaid Services. Accessed August 14, 2023. <https://www.cms.gov/files/document/2023-hcpcs-application-summary-quarter-2-2023-drugs-and-biologicals.pdf> 4. Medicare program. Discarded drugs and biologicals – JW modifier and JZ modifier policy. Frequently asked questions. Centers for Medicare & Medicaid Services (CMS). Accessed July 21, 2023. <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/JW-Modifier-FAQs.pdf> 5. Syfovre. Prescribing information. Apellis Pharmaceuticals, Inc.; 2023. 6. Proposed rule on revising the national drug code format. US Food and Drug Administration. Updated December 27, 2022. Accessed July 18, 2023. <https://www.fda.gov/drugs/drug-approvals-and-databases/proposed-rule-revising-national-drug-code-format> 7. Revenue codes. Noridian Healthcare Solutions. Updated June 28, 2022. Accessed July 18, 2023. <https://med.noridianmedicare.com/web/jea/topics/claim-submission/revenue-codes>